[Federal Register Volume 70, Number 75 (Wednesday, April 20, 2005)]
[Notices]
[Pages 20588-20589]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-7850]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Human Anesthetic 
Formulation Based Upon Cyclodextrin Carriers

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in 
U.S. Patent No. 6,407,079, entitled ``Pharmaceutical compositions 
containing drugs which are instable or sparingly soluble in water and 
methods for their preparation,'' to Jurox Pty Ltd., having a place of 
business in Rutherford, Australia. The field of use may be limited to 
the development of injectable anesthetic formulations containing

[[Page 20589]]

Alfaxalone-hydroxypropyl-beta cyclodextrin complex for use in humans. 
The United States of America has an interest in the patent rights of 
this invention.

DATES: Only written comments and/or application for a license, which 
are received by the NIH Office of Technology Transfer on or before July 
19, 2005 will be considered.

ADDRESSES: Requests for a copy of the patent, inquiries, comments and 
other materials relating to the contemplated license should be directed 
to: Pradeep Ghosh, J.D., Ph.D., M.B.A., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 435-5282; Facsimile: (301) 402-0220; e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: This technology relates to pharmaceutical 
compositions containing drugs that are instable or only sparingly 
soluble in water, and methods for their preparation. The compositions 
are characterized by increased water solubility and improved stability.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 90 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 11, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-7850 Filed 4-19-05; 8:45 am]
BILLING CODE 4140-01-P